IGFBP-7 as a marker of preeclampsia
US11874282B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 23, 2018 |
| Grant date | Jan 16, 2024 |
| Priority date | — |
| Expiry date | Aug 23, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/60
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.